share_log

恒瑞医药:子公司SHR8028滴眼液药物上市许可申请获受理

Hengrui Pharmaceutical: Subsidiary SHR8028 Eye Drop Drug Marketing License Application Accepted

Breakings ·  Mar 20, 2023 16:57
Hengrui Pharmaceutical announced that its subsidiary SHR8028 eye drop drug marketing license application has been accepted.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment